← Guides

Tesamorelin vs CJC-1295: approved vs experimental

Tesamorelin and CJC-1295 are often grouped together because they share the same molecular class — both are synthetic analogs of growth hormone-releasing hormone (GHRH) — and pursue the same general goal: stimulating the body's own growth hormone (GH) secretion through the pituitary somatotrophs, rather than injecting GH directly. That is where the comfortable resemblance ends. The decisive difference is not chemical but regulatory and evidential: tesamorelin is an FDA-approved prescription drug (marketed as Egrifta) for one narrow, specific indication, backed by Phase III trials; CJC-1295 is research-use-only (RUO) material not approved by any agency, with human evidence limited to a handful of pharmacology studies. This guide compares the two at an educational level: what they are, how their status and their backing differ, and why that asymmetry matters. It is not medical advice and includes no dosing.

Same molecular class, same biological axis

What links tesamorelin and CJC-1295 is genuine: both are synthetic analogs of GHRH, growth hormone-releasing hormone. Rather than introducing exogenous growth hormone, they act one step earlier: they bind GHRH receptors on the pituitary somatotrophs and stimulate the release of endogenous GH, which in turn raises IGF-1. The structural difference is one of length and stabilization. Tesamorelin reproduces the GHRH 1-44 sequence with a modification at the N-terminus that protects it from degradation; CJC-1295 starts from the short GHRH 1-29 fragment ('Modified GRF') and, in its DAC (Drug Affinity Complex) version, adds a group that binds covalently to circulating albumin to extend its time in the body from minutes to several days. In both cases, the literature describes the pulsatile, physiologic pattern of GH secretion tending to be preserved rather than replaced by continuous secretion. So far, two molecules from the same family pulling on the same lever. The real divergence appears when you leave biology and enter regulatory territory.

The key distinction: approved drug versus research material

This is the difference no honest comparison can blur. Tesamorelin is an FDA-approved prescription drug in the United States, marketed as Egrifta (and its Egrifta SV/WR versions), with a specific, narrow indication: reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. That means there is a dossier of efficacy and safety reviewed by a regulator, a prescribing label, an identifiable manufacturer, and a framework of medical supervision and pharmacovigilance. CJC-1295 has none of this: it is not approved by the FDA, the EMA, or the MHRA as a medicine for human use, and it circulates as a research chemical (RUO, research use only), outside pharmaceutical manufacturing controls. The practical consequence is large. With tesamorelin, 'approved' does not equal 'free for any use': the approval covers a single indication under prescription and supervision, and any material circulating outside licensed pharmacy channels must equally be treated as RUO. But the existence of that approval means that, at least for that specific use and that population, a regulator has judged the benefit-risk balance to be positive. For CJC-1295, no regulator has made that judgment for any human use.

What backs each one: the evidence asymmetry

The regulatory gap reflects an evidence gap. Tesamorelin is backed by randomized, double-blind, placebo-controlled Phase III clinical trials: pooled analyses of two multicenter trials in roughly 800 adults with HIV and lipodystrophy documented reductions in visceral fat versus placebo at 26 weeks, with a 52-week extension confirming the durability of the effect, and a separate trial reporting reductions in liver fat. It is one of the few peptides in this class with that depth of data. CJC-1295, by contrast, rests its human profile on essentially two pharmacology studies in healthy adult volunteers (Teichman et al., 2006, and Ionescu & Frohman, 2006): short-duration work, in small cohorts, focused on pharmacokinetics, the rise in GH/IGF-1, and the persistence of pulsatility. These are legitimate studies, but they do not answer the questions that matter for continued use: there are no long-term controlled trials on body composition, performance, or aging in the general population. It is worth stressing that even tesamorelin has not established long-term cardiovascular outcomes or safety beyond about a year, and its effects reverse on discontinuation. If the better-supported molecule in the comparison still carries meaningful unknowns, the one with barely any human data multiplies them.

Risks of off-label use and gray-market material

Two layers of risk follow from that asymmetry. The first is mechanistic: both raise endogenous GH and IGF-1, and that sustained elevation carries shared concerns — effects on glucose tolerance and hyperglycemia, fluid retention, joint discomfort, and a class warning against use in people with active or suspected malignancy, because cell-growth signaling can favor proliferation. CJC-1295's DAC formulation adds theoretical questions about immunogenicity and prolonged systemic exposure that are not well characterized in the public literature. The second layer is product quality. Using tesamorelin outside its approved indication, or acquiring CJC-1295 as research material, takes both out of controlled pharmaceutical channels and exposes them to the gray market: vials of unverified composition, possible underfill, impurities, or sterility and labeling problems. The minimum verification — necessary but insufficient on its own — is a Certificate of Analysis from an independent third-party laboratory covering identity, purity by HPLC, quantification, and mass-spectrometry confirmation, checking as well that the laboratory and lot number match the vial in hand. None of this replaces medical supervision, and none of it turns an unapproved use into a decision backed by a regulator.

Frequently asked questions

What is the main difference between tesamorelin and CJC-1295?

Their status. Both are GHRH analogs that stimulate the body's own growth hormone, but tesamorelin is an FDA-approved prescription drug (Egrifta) for HIV-associated lipodystrophy, backed by Phase III trials, whereas CJC-1295 is research-use-only (RUO) material not approved by any regulator and with limited human evidence. This answer is educational, not medical advice.

If tesamorelin is approved, does that mean it is free to use?

No. FDA approval covers a single indication — reduction of excess abdominal fat in adults with HIV and lipodystrophy — under prescription and medical supervision, and it is not approved for any other use. In the EU/UK it does not even hold a marketing authorization. Any material circulating outside licensed pharmacy channels must be treated as RUO, just like CJC-1295.

Are they allowed in competitive sport?

No. GH secretagogues and GHRH analogs, the category that both tesamorelin and CJC-1295 fall into, are prohibited at all times for competitive athletes under WADA's S2 category. This information is educational.

✓ Last reviewed · 2026-07-24